Commentary|Videos|July 20, 2023

Luspatercept for Patients With Lower-Risk MDS: Data from the COMMANDS Trial

Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.

Latest CME